Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam Signs Billion Dollar RNAi Deal With Roche

This article was originally published in The Pink Sheet Daily

Executive Summary

Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.

Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.

Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio

Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS066419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel